Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PSNL (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.27% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 304.51M USD | Price to earnings Ratio - | 1Y Target Price 7.33 |
Price to earnings Ratio - | 1Y Target Price 7.33 | ||
Volume (30-day avg) 1047126 | Beta 1.73 | 52 Weeks Range 1.14 - 7.20 | Updated Date 04/1/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.37 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -96.06% | Operating Margin (TTM) -107.81% |
Management Effectiveness
Return on Assets (TTM) -17.23% | Return on Equity (TTM) -48.91% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 168159441 | Price to Sales(TTM) 3.6 |
Enterprise Value 168159441 | Price to Sales(TTM) 3.6 | ||
Enterprise Value to Revenue 1.99 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88263296 | Shares Floating 52082390 |
Shares Outstanding 88263296 | Shares Floating 52082390 | ||
Percent Insiders 31.34 | Percent Institutions 42.75 |
Analyst Ratings
Rating 4.33 | Target Price 7.98 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. was founded in 2011 and is based in Menlo Park, California. It focuses on advanced genomics for cancer and other complex diseases. Initially focused on whole genome sequencing, it has evolved to provide comprehensive genomic analysis solutions for cancer immunotherapy and precision medicine.
Core Business Areas
- NeXT Platform: Offers comprehensive genomic and proteomic analysis, including whole genome and exome sequencing, RNA sequencing, and proteomic profiling. Primarily used in immuno-oncology and clinical trials.
- Pharma Services: Provides customized genomic solutions for pharmaceutical companies, supporting drug development and clinical trials. This includes biomarker discovery, patient stratification, and monitoring treatment response.
Leadership and Structure
John West is the CEO. The company operates with a functional organizational structure, with departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- NeXT Personal: A comprehensive cancer genomic profiling test designed to identify personalized treatment options. Data on market share or revenue specifically attributed to this product is not publicly available. Competitors include Foundation Medicine (FMI), Guardant Health (GH), and Exact Sciences (EXAS).
- ImmunoID NeXT Platform: A platform to comprehensively profile both the tumor and the immune microenvironment. Data on market share or revenue specifically attributed to this product is not publicly available. Competitors include NanoString Technologies (NSTG) and Adaptive Biotechnologies (ADPT).
Market Dynamics
Industry Overview
The market for cancer genomics and precision medicine is growing, driven by advancements in sequencing technologies and the increasing adoption of personalized treatment approaches. Key drivers include demand for more targeted therapies, expanding use of liquid biopsies, and increased investment in genomics research.
Positioning
Personalis is positioned as a provider of comprehensive genomic and proteomic profiling solutions, focusing on advanced sequencing technologies and immuno-oncology. Its competitive advantage lies in the breadth and depth of its platform, enabling detailed analysis of both tumor and immune system interactions.
Total Addressable Market (TAM)
The TAM for precision oncology is estimated to be in the tens of billions of dollars annually and is growing. Personalis is positioned to capture a share of this market through its advanced genomic solutions for biopharma companies.
Upturn SWOT Analysis
Strengths
- Comprehensive genomic and proteomic platform
- Expertise in immuno-oncology
- Strong relationships with pharmaceutical companies
- Advanced sequencing technologies
Weaknesses
- Reliance on a limited number of key customers
- High operating expenses
- Negative profitability
- Stock Dilution
Opportunities
- Expanding applications of genomics in drug development
- Increasing demand for personalized cancer therapies
- Partnerships with leading research institutions
- Growth in liquid biopsy market
Threats
- Competition from larger, more established genomics companies
- Pricing pressure from commoditization of sequencing services
- Regulatory hurdles for new genomic tests
- Economic downturn affecting research budgets
Competitors and Market Share
Key Competitors
- FMI
- GH
- EXAS
- NSTG
- ADPT
Competitive Landscape
Personalis competes with larger, more established genomics companies. Its competitive advantage lies in its comprehensive genomic and proteomic platform, but it faces challenges in terms of market share and financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Personalis's historical growth has been driven by its collaborations with pharmaceutical companies and its increasing adoption in clinical trials.
Future Projections: Future growth projections would depend on analyst estimates. However, growth is expected to be driven by demand for personalized cancer therapies and expanding applications of genomics in drug development.
Recent Initiatives: Recent strategic initiatives would require gathering the latest information from press releases, investor presentations, and corporate filings.
Summary
Personalis is a specialized genomics company focused on cancer, with strengths in its platform and pharma partnerships. However, it faces stiff competition and has yet to achieve profitability. Future growth depends on capitalizing on opportunities in personalized medicine and expanding its customer base. The company needs to closely monitor cash flow, maintain key customer relationships, and leverage its technological advantages.
Similar Companies
- FMI
- GH
- EXAS
- NSTG
- ADPT
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on available data. Financial data may be outdated and should be verified with official sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.